These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28049746)

  • 1. The global agenda for the prevention of type 2 diabetes.
    Herman WH
    Nutr Rev; 2017 Jan; 75(suppl 1):13-18. PubMed ID: 28049746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.
    Diabetes Prevention Program Research Group
    Diabetes Care; 2003 Sep; 26(9):2518-23. PubMed ID: 12941712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes.
    Roberts S; Barry E; Craig D; Airoldi M; Bevan G; Greenhalgh T
    BMJ Open; 2017 Nov; 7(11):e017184. PubMed ID: 29146638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is type-2 diabetes mellitus preventable?].
    Jermendy G
    Orv Hetil; 2003 Sep; 144(39):1909-17. PubMed ID: 14598569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of metformin in the US diabetes prevention program trial: Simple interpretations need not apply.
    Rittenhouse BE; Alolayan S; Eguale T; Segal AR; Doucette J
    Prev Med; 2024 Jan; 178():107819. PubMed ID: 38092328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
    Flórez H
    Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care.
    Bertram MY; Lim SS; Barendregt JJ; Vos T
    Diabetologia; 2010 May; 53(5):875-81. PubMed ID: 20135088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes prevention programs.
    Ramachandran A; Snehalatha C
    Med Clin North Am; 2011 Mar; 95(2):353-72, viii. PubMed ID: 21281838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of diabetes: a strategic approach for individual patients.
    Shin JA; Lee JH; Kim HS; Choi YH; Cho JH; Yoon KH
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():79-84. PubMed ID: 23280871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of diabetes: more answers, more questions.
    Misra A
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):831-2. PubMed ID: 26377053
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill".
    Srinivasan S; Florez JC
    Clin Pharmacol Ther; 2015 Aug; 98(2):162-9. PubMed ID: 25974616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes: Strategies to prevent the type 2 diabetes mellitus epidemic.
    Robertson RP; Kendall DM; Seaquist ER
    Nat Rev Endocrinol; 2010 Mar; 6(3):128-9. PubMed ID: 20173772
    [No Abstract]   [Full Text] [Related]  

  • 14. Simulating lifestyle and medical interventions to prevent type-2 diabetes: an economic evaluation for Belgium.
    Vandenberghe D
    Eur J Health Econ; 2022 Mar; 23(2):237-248. PubMed ID: 34390431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summaries for patients. The outcomes and costs of diabetes prevention with a diet and exercise program or metformin: a computer model.
    Ann Intern Med; 2005 Aug; 143(4):I22. PubMed ID: 16103465
    [No Abstract]   [Full Text] [Related]  

  • 16. Achievable cost saving and cost-effective thresholds for diabetes prevention lifestyle interventions in people aged 65 years and older: a single-payer perspective.
    Anderson JM
    J Acad Nutr Diet; 2012 Nov; 112(11):1747-54. PubMed ID: 23102174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.
    Cefalu WT; Buse JB; Tuomilehto J; Fleming GA; Ferrannini E; Gerstein HC; Bennett PH; Ramachandran A; Raz I; Rosenstock J; Kahn SE
    Diabetes Care; 2016 Jul; 39(7):1186-201. PubMed ID: 27631469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reflecting on type 2 diabetes prevention: more questions than answers!
    Rosenstock J
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():3-11. PubMed ID: 17877541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program.
    O'Brien MJ; Whitaker RC; Yu D; Ackermann RT
    Prev Med; 2015 Aug; 77():125-30. PubMed ID: 26024851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.